Listen

Press releases

Receive e-mail alerts

Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
December 11, 2019 at 12:00 PM UTC
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
November 21, 2019 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific Conferences
November 18, 2019 at 12:23 PM UTC
Internal link ProQR to Present at Upcoming Investor Conferences
November 13, 2019 at 12:00 PM UTC
Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019
November 06, 2019 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 18, 2019 at 12:20 PM UTC
Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares
October 16, 2019 at 03:17 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 15, 2019 at 09:15 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10
October 15, 2019 at 08:08 PM UTC
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10
October 11, 2019 at 10:02 AM UTC
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
October 10, 2019 at 10:00 AM UTC
Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
October 07, 2019 at 11:00 AM UTC
Internal link ProQR to Present at Two Investor Conferences in October
September 30, 2019 at 11:00 AM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
September 09, 2019 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)
August 12, 2019 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the Second Quarter of 2019
August 07, 2019 at 11:00 AM UTC
Internal link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10
July 29, 2019 at 04:37 PM UTC
Internal link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10
July 29, 2019 at 11:00 AM UTC
Internal link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July
July 02, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the JMP Securities Life Sciences Conference
June 03, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the RBC Capital Markets Healthcare Conference
May 15, 2019 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the First Quarter of 2019
May 08, 2019 at 11:00 AM UTC
Internal link ProQR to Present at Three Scientific Conferences in April
April 22, 2019 at 11:00 AM UTC
Internal link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
April 18, 2019 at 11:00 AM UTC
Internal link ProQR Announces Annual Meeting of Shareholders
April 18, 2019 at 11:00 AM UTC

Press releases

Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Internal link ProQR to Present at Upcoming Scientific Conferences

Internal link ProQR to Present at Upcoming Investor Conferences

Internal link ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10

Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

Internal link ProQR to Present at Two Investor Conferences in October

Internal link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)

Internal link ProQR Announces Financial Results for the Second Quarter of 2019

Internal link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10

Internal link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10

Internal link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July

Internal link ProQR to Present at the JMP Securities Life Sciences Conference

Internal link ProQR to Present at the RBC Capital Markets Healthcare Conference

Internal link ProQR Announces Financial Results for the First Quarter of 2019

Internal link ProQR to Present at Three Scientific Conferences in April

Internal link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board

Internal link ProQR Announces Annual Meeting of Shareholders